Boston Sci., St. Jude settle patent suits
This article was originally published in The Gray Sheet
Executive Summary
Both firms appear to benefit from a settlement that resolves four patent disputes related to the firms' cardiac rhythm management and neuromodulation devices. According to the July 31 announcement, the companies also have reached an accord to limit legal parameters for two additional suits, one of which dates back to 1996 (1"The Gray Sheet" Feb. 18, 2002, In Brief). The agreement bars Boston Scientific from pursuing lost profits and caps royalties at 3% of revenue from sales found to have infringed the patent in question. The companies agreed to cross-license certain of their cardiac rhythm management and neuromodulation patents. St. Jude describes the cross-license agreements as "worldwide" and "royalty free" in a filing with the Securities & Exchange Commission...